Boston Scientific Corp (BSX)vsInfuSystems Holdings Inc (INFU)
BSX
Boston Scientific Corp
$69.78
+2.39%
HEALTHCARE · Cap: $101.28B
INFU
InfuSystems Holdings Inc
$9.79
+1.03%
HEALTHCARE · Cap: $195.23M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 13895% more annual revenue ($20.07B vs $143.44M). BSX leads profitability with a 14.4% profit margin vs 4.6%. BSX appears more attractively valued with a PEG of 0.75. BSX earns a higher WallStSmart Score of 63/100 (C+).
BSX
Buy63
out of 100
Grade: C+
INFU
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+1.2%
Fair Value
$70.62
Current Price
$69.78
$0.84 discount
Margin of Safety
+47.5%
Fair Value
$14.51
Current Price
$9.79
$4.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
15.9% revenue growth
Generating 1.0B in free cash flow
Earnings expanding 123.9% YoY
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
4.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.
Bull Case : INFU
The strongest argument for INFU centers on EPS Growth.
Bear Case : BSX
The primary concerns for BSX are P/E Ratio.
Bear Case : INFU
The primary concerns for INFU are PEG Ratio, P/E Ratio, Market Cap. Thin 4.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
BSX profiles as a growth stock while INFU is a value play — different risk/reward profiles.
INFU carries more volatility with a beta of 1.63 — expect wider price swings.
BSX is growing revenue faster at 15.9% — sustainability is the question.
BSX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (63/100 vs 53/100) and 15.9% revenue growth. INFU offers better value entry with a 47.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
InfuSystems Holdings Inc
HEALTHCARE · MEDICAL DEVICES · USA
InfuSystem Holdings, Inc., provides infusion pumps and related products and services in the United States and Canada. The company is headquartered in Rochester Hills, Michigan.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?